How I treat acute myeloid leukemia

Jacob M. Rowe, Martin S. Tallman

Research output: Contribution to journalArticlepeer-review

154 Scopus citations

Abstract

More than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML). Despite considerable progress during the past 3 decades in the therapy of AML, two-thirds of young adults and 90% of older adults still die of their disease. The reported median age has increased over the past few decades, mostly because of a greater willingness of physicians to diagnose and treat older patients, and now is 72 years. The greatest challenge is in this age group. However, much improvement in therapy is needed for all adults with AML. Recent advances in allogeneic transplantation, a better understanding of prognostic factors, and development of targeted agents have only modestly improved overall outcome when large populations of patients are considered. Although an explosion in knowledge about the molecular pathogenesis ofAMLhas outpaced treatment advances, such insights hold promise for the development of new therapies directed at specific molecular abnormalities that perturb malignant cell survival pathways. The current approach in 2010 to the management of this disease is presented through a discussion of illustrative cases.

Original languageEnglish (US)
Pages (from-to)3147-3156
Number of pages10
JournalBlood
Volume116
Issue number17
DOIs
StatePublished - Oct 28 2010

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint

Dive into the research topics of 'How I treat acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this